Business ❯ Biotechnology ❯ Pharmaceuticals

Immunotherapy

Anktiva Cancer Treatment Collaboration Market Trends

Investors Vie to Lead ImmunityBio Securities Suit

An FDA warning about misleading Anktiva promotions has turned investor losses into the central issue in the fight over who will control the case.

ImmunityBio Investor Lawsuits Push Toward May 26 Lead-Plaintiff Deadline

ImmunityBio Investors Face May 26 Lead-Plaintiff Deadline in Securities Suit Tied to FDA Anktiva Rebuke

ImmunityBio Securities Fight Intensifies After FDA Rebuke Over Anktiva Claims

ImmunityBio Investors Urged to Seek Lead Role in Suit After FDA Rebuke Over Anktiva Ads

Investor Lawsuits Build After FDA Rebukes ImmunityBio Over Anktiva Promotion

Securities Class Action Filed Against ImmunityBio After FDA Flags Anktiva Marketing

ImmunityBio Faces Growing Securities Suits After FDA Flags Misleading Anktiva Claims